Ildong Pharmaceutical

Ildong Pharmaceutical, established in 1941, is a prominent South Korean pharmaceutical entity specializing in the development of innovative therapeutic solutions. The company maintains a robust R&D pipeline focused on high-unmet-need therapeutic areas, including oncology, immune-oncology, endocrinology, liver fibrosis, and neurology. By leveraging decades of expertise, Ildong Pharmaceutical provides a comprehensive portfolio of ethical drugs (ETC) and over-the-counter (OTC) products designed to serve both healthcare professionals and the general consumer market.

Operating with a workforce of 1,000-5,000 employees, the organization maintains a significant presence in the Asian healthcare sector. The company reported annual revenue of $436.2M, reflecting its stable market position and operational scale. Headquartered in Seoul, South Korea, Ildong Pharmaceutical continues to expand its influence through strategic investments in pharmaceutical research and development, ensuring high-quality service delivery across its diverse product range.

Publicly traded under the ticker KRX: 249420, the firm remains committed to advancing medical science through rigorous clinical research and technological integration. Meet Ildong Pharmaceutical's team to gain insights into the leadership driving these strategic initiatives. As a key player in the regional pharmaceutical landscape, the company focuses on sustainable growth and the development of novel therapeutic options to address complex health challenges, solidifying its reputation as a leader in the South Korean healthcare industry.